e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 396.70K | 405.60K | 411.30K | 490.70K | 587.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 396.70K | 405.60K | 411.30K | 490.70K | 587.90K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 396.70K | 405.60K | 411.30K | 490.70K | 587.90K |
| SG&A Expenses | 4.82M | 4.59M | 4.33M | 4.24M | 4.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.61M | 16.74M | 15.79M | 14.24M | 13.09M |
| Operating Income | -17.21M | -16.34M | -15.38M | -13.75M | -12.50M |
| Income Before Tax | -16.32M | -15.42M | -14.44M | -13.01M | -11.95M |
| Income Tax Expenses | -2.39M | -2.31M | -2.22M | -2.00M | -1.83M |
| Earnings from Continuing Operations | -13.93 | -13.11 | -12.22 | -11.02 | -10.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.93M | -13.11M | -12.22M | -11.02M | -10.12M |
| EBIT | -17.21M | -16.34M | -15.38M | -13.75M | -12.50M |
| EBITDA | -16.78M | -15.91M | -14.96M | -13.36M | -12.12M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 2.34B | 2.30B | 2.27B | 2.21B | 2.15B |
| Average Diluted Shares Outstanding | 2.34B | 2.30B | 2.27B | 2.21B | 2.15B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |